DEFA14A: Avadel Board Deems Lundbeck Bid Superior to Alkermes Deal

Avadel Pharmaceuticals' Board of Directors has declared an unsolicited acquisition proposal from H. Lundbeck A/S, valuing the company at up to $2.4 billion, as superior to its existing agreement with Alkermes plc.

Summary

• Avadel Pharmaceuticals' Board of Directors has determined that an unsolicited acquisition proposal from H. Lundbeck A/S constitutes a "Company Superior Proposal" compared to its existing transaction agreement with Alkermes plc.
• The Lundbeck Proposal values Avadel at up to $23.00 per ordinary share, representing a total equity value of approximately $2.4 billion.
• This represents an approximate 29% premium to Avadel's closing price as of October 21, 2025, the last business day prior to the announcement of the Alkermes acquisition.
• The Lundbeck Proposal includes $21.00 per ordinary share in cash at closing and two non-transferable contingent value rights (CVRs).
• The CVRs offer potential additional cash payments of $1.00 per share if LUMRYZ and valiloxybate collectively reach $450 million in U.S. annual net sales by December 31, 2027, and another $1.00 per share if they reach $700 million by December 31, 2030.
• The Alkermes Transaction Agreement remains in full effect, and Avadel's Board has not yet changed its recommendation in support of the Alkermes acquisition.
• Alkermes has a five-business-day period to discuss or negotiate potential amendments to its agreement.

Sentiment

Score: 8

Explanation: The announcement of a superior acquisition proposal from Lundbeck, offering a significant premium and potential CVR upside, is a very positive development for Avadel shareholders. While the deal is not finalized and a matching period with Alkermes is active, the competitive bidding environment strongly suggests a higher ultimate acquisition price for the company.

Positives

• Lundbeck's proposal offers a higher valuation of up to $23.00 per share, a 29% premium over the pre-Alkermes announcement price.
• The proposal includes a significant cash component of $21.00 per share at closing, providing immediate value to shareholders.
• Contingent Value Rights (CVRs) offer potential upside of an additional $2.00 per share based on future sales performance of LUMRYZ and valiloxybate.
• The existence of a superior proposal creates a competitive bidding environment, potentially leading to an even higher offer from Alkermes or Lundbeck.

Negatives

• The acquisition is not certain, as the Lundbeck proposal is subject to various closing conditions, including Avadel shareholder and regulatory approvals.
• The contingent value rights (CVRs) are non-transferable, limiting liquidity for these potential future payments.
• The CVR payments are contingent on specific sales targets ($450 million by December 31, 2027, and $700 million by December 31, 2030) for LUMRYZ and valiloxybate, introducing performance risk.
• The ongoing negotiation period with Alkermes introduces uncertainty regarding the final outcome of the acquisition.

Risks

• Inability of the parties to consummate the acquisition in a timely manner or at all.
• Failure to satisfy (or waiver of) conditions to the acquisition, including shareholder and required regulatory approvals.
• Potential impact of the unsolicited proposal from Lundbeck or the possibility of more competing offers, which could complicate the process.
• Potential delays in consummating the acquisition.
• Inability to timely and successfully achieve the anticipated benefits of the acquisition.
• Impact of health pandemics on the parties' respective businesses and the actions taken in response.
• Occurrence of any event, change, or circumstance that could lead to the termination of the transaction agreement.
• Effect of the announcement or pendency of the acquisition on Avadel's business relationships, operating results, and business generally.
• Costs related to the acquisition process.
• Outcome of any legal proceedings that may be instituted against the parties or their directors or officers related to the transaction agreement or the acquisition.

Future Outlook

Avadel's Board has determined that the unsolicited proposal from Lundbeck constitutes a Company Superior Proposal, triggering a five-business-day negotiation period with Alkermes. The outcome of these negotiations will determine the future direction of the acquisition, with potential for an amended Alkermes agreement or a definitive agreement with Lundbeck. The company's future prospects are tied to the successful consummation of an acquisition and the performance of its key products, LUMRYZ and valiloxybate, which are tied to contingent value rights.

Management Comments

• Avadel will have no further comment on the Lundbeck Proposal or potential discussions with Alkermes until the Board has completed discussions and/or negotiations with Alkermes during the matching period pursuant to the terms of the Alkermes Transaction Agreement.

Industry Context

The biopharmaceutical industry frequently sees M&A activity driven by companies seeking to expand product portfolios, gain market share, or acquire promising drug candidates. This competitive bid for Avadel, a company with an FDA-approved narcolepsy treatment (LUMRYZ), highlights the value placed on specialized therapeutic assets and established commercial products. The inclusion of contingent value rights (CVRs) in Lundbeck's proposal reflects a common strategy in biotech M&A to bridge valuation gaps and share future product performance risks and rewards, particularly for assets with significant but unproven sales potential like valiloxybate.

Corporate Governance

Legal Proceedings

• Potential legal proceedings may be instituted against the parties or their directors/officers related to the transaction agreement or the acquisition.

Stakeholder Impact

• Shareholders: Potential for increased acquisition price and value realization due to the superior proposal and competitive bidding. Will need to vote on the final acquisition.
• Employees: Uncertainty regarding future employment and integration plans under a new owner (Lundbeck or potentially an amended Alkermes deal).
• Customers: Potential changes in product strategy, sales, and support for LUMRYZ and valiloxybate depending on the acquiring entity.
• Creditors: Potential impact on debt structure and covenants depending on the financing of the acquisition.

Next Steps

• Avadel will engage in discussions or negotiations with Alkermes for five business days if requested, regarding potential amendments to the Alkermes Transaction Agreement.
• Avadel's Board will determine if the Lundbeck Proposal continues to be a Company Superior Proposal after considering any Alkermes amendments.
• If the Lundbeck Proposal remains superior, Avadel may be entitled to terminate the Alkermes Transaction Agreement.
• Lundbeck must announce a firm intention to make an offer or state it does not intend to make an offer by a specific deadline related to the Avadel shareholder meeting for the Alkermes scheme of arrangement.
• Avadel shareholders will eventually vote on the acquisition.

Key Dates

Recommendation

The declaration of Lundbeck's proposal as a 'Company Superior Proposal' creates a bidding war scenario, highly likely to result in a higher acquisition price for Avadel shareholders. The offer of up to $23.00 per share, including a significant cash component and CVRs, represents a substantial premium. While the Alkermes agreement is still in effect, the five-day matching period provides an opportunity for Alkermes to sweeten its offer, or for Lundbeck to proceed with its superior bid. This situation presents a compelling opportunity for investors to benefit from the increased valuation.

Keywords

Avadel Pharmaceuticals, Lundbeck, Alkermes, Acquisition, Merger, Takeover, Superior Proposal, LUMRYZ, Contingent Value Right, Biopharmaceutical, Narcolepsy, AVDL, ALKS